16:8 Fasting Cuts IBS Symptom Scores by 100 Points in 8 Weeks

Irritable bowel syndrome affects an estimated 5–10% of the global population and imposes a heavy burden on quality of life, yet many patients find little lasting relief from current options like the low-FODMAP diet, probiotics, or pharmacotherapy. All established dietary strategies focus on what people eat; this Norwegian pilot is among the first to ask whether when people eat matters just as much.

Researchers recruited 134 adults with physician-diagnosed IBS from the Norwegian Gastrointestinal Association and enrolled them in an 8-week 16:8 TRE protocol running from September to November 2024. Participants fasted for 16 consecutive hours daily and confined all eating to an 8-hour window of their own choosing. No foods were forbidden, no calorie targets were set, and the explicit goal was weight maintenance. Support was delivered via digital information sessions and a private Facebook group. Outcomes were measured with the validated IBS Symptom Severity Scale (IBS-SSS, range 0–500) at baseline and week 8.

Of 97 completers (90% women, mean age 42.5 years), the mean IBS-SSS total score fell by 100.2 points (SD 112.3, p < 0.001). Subgroup breakdowns showed IBS-constipation benefited most (−125.2 points, p < 0.001), followed by IBS-mixed (−93.1, p < 0.001) and IBS-diarrhea (−76.0, p < 0.005). The small IBS-unclassified group (n = 6) showed no significant change. Sixty participants (61.9%) crossed the 50-point threshold for clinically meaningful improvement. Severe-severity cases dropped from 39% at baseline to 10% post-intervention, while mild-severity cases nearly tripled (15.5% → 40.2%). Twelve individuals (12.4%) achieved full remission. Self-rated physical and mental health scores also improved significantly.

The proposed mechanisms are biologically plausible: fasting periods promote gastrointestinal motility patterns (migrating motor complex activity), reduce luminal antigen exposure, modulate the gut microbiota, and dampen low-grade immune activation—all pathways implicated in IBS pathophysiology. TRE may also reduce overall meal frequency, limiting cumulative FODMAP load without requiring explicit dietary restriction.

Critically, this study lacks a control group, so placebo effects, regression to the mean, and seasonal variation cannot be excluded. Adherence was self-reported with no objective tracking, IBS diagnosis was not independently verified, dropout was 28%, and the sample was overwhelmingly female. Despite these limitations, the magnitude and consistency of improvement across subtypes are noteworthy and strongly justify a well-powered randomized controlled trial.